A Network Medicine Approach to Investigating ME/CFS Pathogenesis in Severely Ill Patients: A Pilot Study, 2024, Hung, Davis, Xiao

Dolphin

Dolphin

Senior Member (Voting Rights)
Now published - link
*****************

Preprint
https://www.medrxiv.org/content/10.1101/2024.09.26.24314417v1

A Network Medicine Approach to Investigating ME/CFS Pathogenesis in Severely Ill Patients: A Pilot Study

Li-Yuan Hung, Chan-Shuo Wu, Chia-Jung Chang, Peng Li, Kimberly Hicks, Becky Taurog, Joshua J Dibble, Braxton Morrison, Chimere L Smith, Ronald W Davis, Wenzhong Xiao
doi: https://doi.org/10.1101/2024.09.26.24314417


Abstract

This pilot study harnessed the power of network medicine to unravel the complex pathogenesis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

By utilizing a network analysis on whole genome sequencing (WGS) data from the Severely Ill Patient Study (SIPS), we identified ME/CFS-associated proteins and delineated the corresponding network-level module, termed the SIPS disease module, together with its relevant pathways.

This module demonstrated significant overlap with genes implicated in fatigue, cognitive disorders, and neurodegenerative diseases.

Our pathway analysis revealed potential associations between ME/CFS and conditions such as COVID-19, Epstein-Barr virus (EBV) infection, neurodegenerative diseases, and pathways involved in cortisol synthesis and secretion, supporting the hypothesis that ME/CFS is a neuroimmune disorder.

Additionally, our findings underscore a potential link between ME/CFS and estrogen signaling pathways, which may elucidate the higher prevalence of ME/CFS in females.

These findings provide insights into the pathogenesis of ME/CFS from a network medicine perspective and highlight potential therapeutic targets.

Further research is needed to validate these findings and explore their implications for improving diagnosis and treatment.

https://twitter.com/user/status/1839715589121814815
Click to expand...
 
Last edited by a moderator:
Ron Davis' lab, funding from OMF and the Patient-Led Collaborative

Our research centers on the Severely Ill Patient Study (SIPS) cohort, which includes patients enduring the most severe symptoms of ME/CFS (Chang et al., 2021). These individuals suffer from profound fatigue, cognitive impairment, and a significantly reduced quality of life. Previous analyses of this cohort revealed unique sleep profiles, cognitive deficits, and markedly low morning cortisol levels.
Click to expand...

In the Severely Ill Patient Study (SIPS) (Chang et al., 2021), we investigated the medical conditions of 20 ME/CFS patients exhibiting severe symptoms, as previously documented. These individuals met the International Consensus Criteria for ME/CFS (ME-ICC) (Carruthers et al., 2011) and were confined to their homes, remaining sedentary and reclined for over 14 hours daily. Their SF-36 physical functioning scores and Karnofsky Performance Status Index (Karnofsky and Burchenal,1949) scores were both below 70.
Click to expand...

We know that the body adapts to a lack of physical challenge - there is no need to produce high levels of cortisol if someone is sedentary at home. There is particularly no need to have a marked morning peak cortisol level if a person is not getting up and rushing about to get on with their day. So, give the strong likelihood that any differences from mean levels of healthy controls are just an environmental adaptation, I'll be interested to see if there is any genetic difference tied to low cortisol levels.

WGS was performed on the blood samples from the 20 SIPS patients, and high-confidence variants were filtered based on several criteria (see Methods), resulting in 2,798,019 variants for further analysis. Using the American College of Medical Genetics and Genomics (ACMG) criteria, we identified 103 pathogenic or likely pathogenic variants (Qiagen IVA). These were then compared to
background population data, leading to the removal of 7 common SNVs. The remaining 96 variants were aggregated at the gene level (Table S1). Among them, 9 genes were found to affect at least 2 (10%) of the 20 patients (Figure 1, Table S1).
Click to expand...
These are small numbers. I mean, fair enough to look to see if there is some genetic story and a finding even in one person could be helpful in identifying a subset or misdiagnosis, but 'at least 2 patients' is a low bar. The abstract should have included the details of the sample size and how common the identified genes were in the sample.
 
We examined the nine genes with recurrent variants in the SIPS patients (Figure 1), specifically ACADL, BRCA1, CFTR, COX10, HABP2, MFRP, PCLO, PRKN, and ZFPM2. Given the defining characteristic of cognitive abnormalities in SIPS patients, it was crucial to assess the relevance of these genes to their symptoms. Seven of the nine genes (77.8%) have previously been linked to cognitive impairment or neurological functions.

For instance, BRCA1 is involved in maintaining genomic stability and has implications in neurodegeneration and stress-induced senescence (Leung and Hazrati, 2021; Suberbielle et al., 2015). The PRKN gene is associated with Parkinson's disease, characterized by both motor and non-motor symptoms (Lücking et al., 2000). CFTR's expression in the nervous system may influence mood, memory, energy balance, olfaction, motor function, respiration, and autonomic control of visceral organs (Reznikov, 2017). Mutations in the COX10 gene, crucial for cellular respiration, have been linked to various peripheral neuropathy disorders (Fünfschilling et al., 2012; Kuroha et al., 2022). MFRP is tied to eye development, with mutations affecting retinal microglia (Kumari et al., 2022). PCLO, encoding the Piccolo protein essential for synaptic transmission, has mutations linked to pontocerebellar hypoplasia, a rare neurodegenerative disorder (Ackermann et al., 2019; Ahmed et al., 2015). ZFPM2 is involved in the development of GABAergic neurons in specific brain regions (Morello et al., 2020).
Click to expand...
 
Hutan said:
Ron Davis' lab, funding from OMF and the Patient-Led Collaborative





We know that the body adapts to a lack of physical challenge - there is no need to produce high levels of cortisol if someone is sedentary at home. There is particularly no need to have a marked morning peak cortisol level if a person is not getting up and rushing about to get on with their day. So, give the strong likelihood that any differences from mean levels of healthy controls are just an environmental adaptation, I'll be interested to see if there is any genetic difference tied to low cortisol levels.


These are small numbers. I mean, fair enough to look to see if there is some genetic story and a finding even in one person could be helpful in identifying a subset or misdiagnosis, but 'at least 2 patients' is a low bar. The abstract should have included the details of the sample size and how common the identified genes were in the sample.
Click to expand...
Yeah... hopefully the DECODE ME gene study should be more helpful given the large sample size.
 
Small sample but they do also blend two other cohorts in and look for commonalities.

This is not game-changing research or cure-finding research but it probably help tip the funding paradigm slightly in the direction of EBV and neuro issues.

And when DecodeME comes out (suppposedly in August 2025) it will be useful to cross-reference this.
 
You must log in or register to reply here.
Back
Top Bottom